Dr. Pashtoon Kasi is the Englander Institute for Precision Medicine’s Director for Liquid Biopsy Research. He is an oncologist and researcher focused on treating patients with gastrointestinal cancers and other solid tumors using novel clinical...
Read more
There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to an analysis by investigators from Weill Cornell...
Read more
Immunotherapy unleashes the power of the immune system to fight cancer. However, for some patients, immunotherapy doesn’t work, and new research may help explain why. When immune cells called T lymphocytes infiltrate malignant tumors, the genetic ...
Read more
We are pleased to introduce our newest EIPM Member Peter Waltman, Ph.D. Dr. Waltman is a Research Associate in Bioinformatics at the Englander Institute for Precision Medicine, working in the labs of Director Olivier Elemento, Ph.D., and Andrea...
Read more
Immunotherapy for Lung Cancer Immunotherapy drugs, also known as immune checkpoint inhibitors, target cancer cells by recruiting and activating the body’s own immune cells to kill cancer cells. This approach—used for about seven years—has...
Read more
Immunotherapy Extends Survival in Esophageal Cancer December 02, 2020 The immunotherapy drug pembrolizumab, known by its brand name Keytruda, is a safe and effective option for patients with locally advanced and metastatic squamous cell...
Read more
Preclinical Model Suggests Why Common Immunotherapy May Not be Effective at Treating Breast Cancer A preclinical model of a common type of breast cancer provides new insight into why an immunotherapy known as checkpoint inhibition has not yet...
Read more
WE ARE PLEASED TO INTRODUCE YOU TO ANOTHER GIFTED EIPM INVESTIGATOR, BISHOY FALTAS, M.D., WHO STUDIES BLADDER CANCER. AMONG OTHER RESEARCH GOALS, HIS TEAM WILL ESTABLISH BLADDER CANCER ORGANOIDS, WHICH ARE MINI TUMOR ‘AVATARS’ FROM EACH PATIENT...
Read more